FindMyKOL

Lydia Gedmintas, MD

Basic profile

Brigham and Women's Hospital

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionBoston, MA · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: RegionalLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Lydia Gedmintas is a Rheumatology/Immunology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 18 publications with 1,265 citations (h-index 12).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
18publications

Publications indexed by OpenAlex. Counts exclude supporting files.

1,265citations

Citations across these publications.

12h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Sandoz Inc.
    Program year20231 payment
    $18

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    34.3%
    Folate Analog Metabolic Inhibitor14.4%
    Methotrexate100%
    Part D≥34 patients
    TNF inhibitor10.7%
    Enbrel Sureclick44%Humira(Cf) Pen41%Humira Pen15%
    Part D<11 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    22.3%
    Corticosteroid21%
    Prednisone100%
    Part D≥46 patients
    Antidiarrheal microorganisms1.3%
    Folic Acid100%
    Part D<11 patients
  • Nervous system

    17.1%
    Nonsteroidal Anti-inflammatory Drug7.3%
    Meloxicam81%Ibuprofen19%
    Part D<11 patients
    Gabapentinoids4.3%
    Gabapentin68%Pregabalin32%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)37% facility · 63% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”